CellDom Wins $1.5M NIH Grant To Develop Single-Cell Analysis Platform

Sep 12, 2018

|

NEW YORK (GenomeWeb) – Celldom said today that it has received a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health.

Celldom will use the award, administered by National Institute of General Medical Sciences, to advance the next generation of its high-throughput single cell analysis platform to analyze heterogeneity in cell populations for research and drug discovery.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Just "Preliminary" Work

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Australia's Gene Editing Policy Approach

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

Some Big Trees

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

This Week in PNAS

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Apr

24

Featured Webinar

Metabolomics Analyses to Elucidate Systemic Processes in Human Health and Disease

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu